News

Medpace Logo

For Immediate Release: April 5, 2019

Contact
Julie Hopkins
513-579-9911 x 12627
j.hopkins@medpace.com

Medpace Continues to Strengthen its Medical Expertise in
Hematology/Oncology and Advanced Therapies

Dr. Petr Seidl Joins Medpace as Senior Medical Director

CINCINNATI, OH — (April 5, 2019) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO), announced that Petr Seidl, MD, MBA has joined Medpace as Senior Medical Director. Medpace’s unique, scientifically-driven approach to clinical research embeds medical expertise throughout trial design and execution, providing a high-science approach to clinical development. With the addition of Dr. Seidl, Medpace can offer Sponsors even deeper expertise across a broad spectrum of diseases and technologies.

About Petr Seidl, MBA, MD

Dr. Petr Seidl is board certified in urology and brings over 20 years of biopharmaceutical and CRO clinical research experience to Medpace’s medical leadership team. His oncologic experience is extensive having worked in solid tumors (prostate cancer, bladder cancer, breast cancer, ovarian cancer, lung cancer) and hematology-oncology (leukemias, lymphomas). In addition to his therapeutic expertise, he also has clinical research experience with various technology platforms including small molecules, therapeutic proteins, monoclonal antibodies, antibody-drug conjugates, antisense drugs and advanced therapy medicinal products in global Phase I/II and Phase III programs. Prior to joining Medpace, he served as the Director of Medical Affairs for another global CRO. Dr. Seidl received his medical degree from Charles University in the Czech Republic. He also holds an MBA from The Open University Business School in Milton Keynes, England.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,900 people across 36 countries.